Selenium Or Compound Thereof Patents (Class 424/702)
  • Patent number: 11504327
    Abstract: The present invention provides a nanoparticle dispersion for topical delivery to skin of a mammal. The nanoparticle dispersion includes: one or more hydrophobic bioactive agents or one or more hydrophobic drugs; one or more surfactants; one or more water immiscible oils; and water. Methods of preparing nanoparticle dispersions by hot melt extrusion are also provided.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: November 22, 2022
    Inventor: Eric Morrison
  • Patent number: 10543228
    Abstract: The invention relates to compositions containing selenite-containing compounds and pharmaceutically acceptable acids, selected from citric acid, acetic acid, malic acid, carbonic acid, sulphuric acid, nitric acid, hydrochloric acid, fruit acids or mixtures thereof, for use for treating cervical inflammations, dysplasia and/or carcinomas. The invention further relates to methods of using such compositions.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: January 28, 2020
    Assignee: SELO MEDICAL GMBH
    Inventor: Norbert Fuchs
  • Patent number: 10201566
    Abstract: The invention relates to compositions containing selenite-containing compounds and pharmaceutically acceptable acids, selected from citric acid, acetic acid, malic acid, carbonic acid, sulphuric acid, nitric acid, hydrochloric acid, fruit acids or mixtures thereof, for use for treating cervical inflammations, dysplasia and/or carcinomas. The invention further relates to methods of using such compositions.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: February 12, 2019
    Assignee: SELO MEDICAL GMBH
    Inventor: Norbert Fuchs
  • Patent number: 10058529
    Abstract: A nootropic combination for increasing cognitive functioning. The combination includes a phosphodiesterase 4 inhibitor and a cyclic adenosine monophosphate increasing agent. In some versions, the phosphodiesterase inhibitor is a flavonoid such as luteolin, and the cyclic adenosine monophosphate increasing agent is a labdane diterpene such as forskolin. The combination can also include one or a combination of L-phenylalanine, L-carnitine, acetyl-L-carnitine, and vitamin B6. In some versions, plant extracts, such as artichoke extract can be used as a source of the PDE4 inhibitor. Methods of using the combination to increase cognitive functioning are also included.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: August 28, 2018
    Inventor: Justin Sher
  • Patent number: 9999621
    Abstract: The invention refers to BTBD9 binders and gephyrin binders for medical use and in particular an artemisinin compound of general formula I for use in the treatment of a diabetes patient, as well as a method of identifying suitable lead candidates.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: June 19, 2018
    Assignee: CeMM—Forschungszentrum für Molekulare Medizin GmbH
    Inventors: Jin Li, Stefan Kubicek
  • Patent number: 9931316
    Abstract: Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, birds, bats and bees. Such compounds and compositions can be used individually or in combination with known medicines or natural products to improve health.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: April 3, 2018
    Inventor: Paul Edward Stamets
  • Patent number: 9833486
    Abstract: The present application relates to compositions comprising selenium (e.g., selenium enriched yeast) and methods of using the same to treat and inhibit obesity, diabetes and related conditions. In particular, the present application provides compositions comprising selenium enriched yeast (e.g., selenium enriched yeast comprising 2% or less inorganic selenium), and methods of using the same to enhance mitochondrial activity and function (e.g., in skeletal muscle and liver) in a subject (e.g., as a therapeutic and/or prophylactic treatment for diabetes, obesity and related conditions).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 5, 2017
    Assignee: ALLTECH, INC.
    Inventors: Ronan Power, Casey Egan, Alexander Yiannikouris, Zi-Jian Lan, Rijin Xiao, Lewis Collen Jackson, Stefan Kwiatkowski
  • Patent number: 9663785
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear Respiratory Factor 1 (NRF1), in particular, by targeting natural antisense polynucleotides of Nuclear Respiratory Factor 1 (NRF1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF1.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: May 30, 2017
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 9592264
    Abstract: A medicine delivery system delivers medicine such as a dietary supplement to improve prostate health and includes an outer capsule containing a saw palmetto extract and an inner capsule within the outer capsule and containing a carotenoid. The outer capsule is formed to dissolve in the stomach when ingested to release the saw palmetto extract into the stomach and the inner capsule is formed to pass into the duodenum to dissolve and release the carotenoid into the duodenum.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: March 14, 2017
    Assignee: U.S. NUTRACEUTICALS, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Patent number: 9248149
    Abstract: The invention features methods and selenium-containing compositions for treating a neoplastic disease in a subject. In particular, the invention features methods for enhancing sensitivity of a tumor to cancer therapy by treating the tumor with an inorganic selenium-containing (iSe) compound and with a cancer therapy, particularly a cancer therapy that also affects the cellular redox status of a tumor cell (e.g., radiation).
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: February 2, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Susan J. Knox, Bryan Husbeck
  • Publication number: 20150147413
    Abstract: The invention features methods and selenium-containing compositions for treating a neoplastic disease in a subject. In particular, the invention features methods for enhancing sensitivity of a tumor to cancer therapy by treating the tumor with an inorganic selenium-containing (iSe) compound and with a cancer therapy, particularly a cancer therapy that also affects the cellular redox status of a tumor cell (e.g., radiation).
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: SUSAN J. KNOX, BRYAN HUSBECK
  • Publication number: 20150140130
    Abstract: A treatment of a neurological disorder, including hypoxia, oxygen-glucose deprivation and acute brain trauma in a subject involves administering an effective amount of selenate or a pharmaceutically acceptable salt thereof to the subject. The treatment prevents incurring a symptom, holds in check a symptom or treats an existing symptom of the neurological disorder.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Inventors: GRANT MORLEY, CHRISTOPHER HOVENS
  • Publication number: 20150110758
    Abstract: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.
    Type: Application
    Filed: January 5, 2015
    Publication date: April 23, 2015
    Inventor: Omar M. Amin
  • Publication number: 20150093454
    Abstract: The present invention relates to a composition comprising alfa-lipoic acid, or a salt or complex thereof, and honokiol, wherein the weight quantity of said honokiol is between 1% and 30% with respect to the total weight of honokiol and alfa-lipoic acid.
    Type: Application
    Filed: April 19, 2013
    Publication date: April 2, 2015
    Inventors: Carlo Terruzzi, Fabio Terruzzi
  • Patent number: 8993001
    Abstract: Methods for treating feline hyperthyroidism comprising (1) administering to a feline an antithyroid agent in conjunction with feeding the feline a composition comprising from about 0.1 to less than about 1 mg/kg iodine or (2) feeding the feline a composition comprising from about 0.1 to less than about 1 mg/kg selenium on a dry matter basis.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: March 31, 2015
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Karen Joy Wedekind, Dale Allen Fritsch, Chadwick Everett Dodd, Timothy Arthur Allen
  • Patent number: 8992999
    Abstract: A composition for preventing or reducing harmful effects of protozoal infection is provided, comprising in one embodiment a yeast cell wall and a preparation derived from oregano. The composition may further include a mineral nutrient selected from selenium and/or zinc. The composition may also include a preparation derived from Yucca. Efficacy of the composition is shown against a variety of protozoal organisms.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: March 31, 2015
    Assignee: Alltech, Inc.
    Inventors: Cepta Duffy, Aidan Joseph Connolly
  • Publication number: 20150044138
    Abstract: The invention relates to a composition comprising: (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, for use in preserving or improving functional synaptic connectivity and/or preserving brain network organization in a subject in need thereof.
    Type: Application
    Filed: March 4, 2013
    Publication date: February 12, 2015
    Applicant: N.V. Nutricia
    Inventors: Marieke Lansbergen, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis, Mattheus Cornelis De Wilde
  • Publication number: 20150044304
    Abstract: The invention relates to a composition comprising: (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, for use in the improvement of the composite NTB score. The invention also provides an improved NTB method comprising an optimized set of individualized tests, in particular for a (prodromal or mild) Alzheimer's or dementia patient.
    Type: Application
    Filed: October 30, 2012
    Publication date: February 12, 2015
    Inventors: Martine Groenendijk, Anke Bongers, Patrick Joseph Gerardus Hendrikus Kamphuis
  • Publication number: 20150017147
    Abstract: The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm3.
    Type: Application
    Filed: June 13, 2014
    Publication date: January 15, 2015
    Applicant: D&E Gillespie Enterprises LLC
    Inventor: John Gillespie
  • Patent number: 8932649
    Abstract: The invention features methods and selenium-containing compositions for treating a neoplastic disease in a subject. In particular, the invention features methods for enhancing sensitivity of a tumor to cancer therapy by treating the tumor with an inorganic selenium-containing (iSe) compound and with a cancer therapy, particularly a cancer therapy that also affects the cellular redox status of a tumor cell (e.g., radiation).
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: January 13, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Susan J. Knox, Bryan Husbeck
  • Publication number: 20150004149
    Abstract: Nutritional products having improved cohesiveness for promoting safer swallowing of food boluses for patients having swallowing conditions are provided as well as methods of making and using such products. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided.
    Type: Application
    Filed: December 17, 2012
    Publication date: January 1, 2015
    Inventors: Adam Burbidge, Jan Engmann, Simina Popa Nita
  • Patent number: 8920851
    Abstract: The present invention relates to the use of selenate or a pharmaceutically acceptable salt thereof in methods and compositions for enhancing the activity of the protein phosphatase PP2A. Methods of reducing phosphorylation of tau protein, inhibiting activity of GSK3 and treating or preventing neurodegenerative diseases are also described.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: December 30, 2014
    Assignee: Velacor Therapeutics Pty Ltd
    Inventors: Christopher Hovens, Niall Corcoran
  • Patent number: 8911724
    Abstract: Provided are methods and compositions for increasing CD4+ cell count in mammals, preferably by at least 25%, while undergoing treatment for various conditions whose treatment can have detrimental effects on immune system function. Such conditions include, but are not limited to, HIV infection, cancer, and hepatitis. The compositions include alpha lipoic acid; acetyl L-carnitine; N-acetyl-cysteine; and optionally: zinc, selenium, vitamin C, bioflavinoid complex, vitamin E, co-enzyme Q10, glutathione, beta-carotene, vitamin A, vitamin B1, vitamin B2, vitamin B6, niacinamide, calcium pantothenate, folic acid, vitamin B12, copper, manganese, chromium, and molybdenum.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 16, 2014
    Assignee: K-PAX Pharmaceuticals, Inc.
    Inventor: Jon D. Kaiser
  • Patent number: 8911798
    Abstract: The present invention relates to oral compositions which are useful for nutrient supplementation. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of patients in various stages of chronic kidney disease and supplementing levels of physiological anti-oxidants, vitamins, and minerals in subjects requiring dialysis therapy.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: December 16, 2014
    Inventor: Ajay Gupta
  • Publication number: 20140348953
    Abstract: Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided.
    Type: Application
    Filed: August 15, 2014
    Publication date: November 27, 2014
    Inventors: George B. Stefano, Patrick Cadet, Kirk J. Mantione, Wei Zhu
  • Publication number: 20140342022
    Abstract: Gene-Eden-VIR is a natural product that safely and effectively decreases the level of fatigue in treated individuals.
    Type: Application
    Filed: May 14, 2013
    Publication date: November 20, 2014
    Inventor: Hanan Polansky
  • Patent number: 8871715
    Abstract: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX) possess the ability to alter expression of genes associated with disease and/or aging while other forms of selenium (e.g., selenomethionine) do not.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: October 28, 2014
    Assignee: Alltech, Inc.
    Inventors: Thomas P. Lyons, Ronan Power
  • Patent number: 8865763
    Abstract: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX) possess the ability to alter expression of genes associated with disease and/or aging while other forms of selenium (e.g., selenomethionine) do not.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: October 21, 2014
    Assignee: Alltech, Inc.
    Inventors: Thomas P. Lyons, Ronan Power
  • Publication number: 20140302169
    Abstract: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Inventor: Richard Roberts
  • Publication number: 20140302178
    Abstract: Gene-Eden-VIR is a natural product that decreases the severity, duration, and frequency of symptoms during a viral infection, including infections with the Human Papillomavirus (HPV), Epstein Barr Virus (EBV), Herpes Simplex Virus (HSV), Human Cytomegalovirus (HCMV), and Hepatitis C Virus (HCV).
    Type: Application
    Filed: April 4, 2013
    Publication date: October 9, 2014
    Inventor: Hanan Polansky
  • Publication number: 20140294787
    Abstract: Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of at least 6. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided.
    Type: Application
    Filed: March 1, 2012
    Publication date: October 2, 2014
    Inventors: Adam Stewart Burbidge, Jan Engmann, Simina Popa Nita
  • Patent number: 8846732
    Abstract: Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB. The treatment of SRB with both a biocide and a metabolic inhibitor provides effective biogenic sulfide inhibition at significantly lower concentrations than would be required if the biocide or metabolic inhibitor was used alone.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: September 30, 2014
    Assignees: ConocoPhillips Company, University Technologies International, Inc.
    Inventors: Gary E. Jenneman, Anne Greene, Gerrit Voordouw
  • Patent number: 8846111
    Abstract: Compositions comprising selenium (e.g., organic selenium (e.g., selenized yeast (e.g., SEL-PLEX))) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment) are provided. For example, compositions comprising selenium (e.g., organic selenium (e.g., selenized yeast (e.g., SEL-PLEX))) and methods of using the same are provided for treating and/or preventing one or more conditions (e.g., problems) disorders, and/or diseases related to establishing and/or maintaining a pregnancy. Compositions and methods of the invention find use in, among other things, research and clinical (e.g., preventative and therapeutic) applications.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: September 30, 2014
    Assignee: Alltech, Inc.
    Inventors: Thomas P. Lyons, Ronan Power
  • Publication number: 20140271927
    Abstract: The present invention provides therapeutic and nutrient compositions comprising Alpha lipoic acid, gammalinolenic acid, chromium, selenium, and optionally iodine for the treatment of diabetic neuropaty. These compositions ameliorate the condition and symptoms associated with the complications of lack of triiodothyronine in the nucleus of target cells, in particular and the pathological effects of the vaso nervorum.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventor: Agustin Andrade
  • Publication number: 20140271558
    Abstract: Beta glucan and fulvic acid can be combined in a dietary supplement as a partial substitute or complete replacement for blue green algae and/or brown seaweed and its derivatives. Beta glucans are widely available as derivatives of Brewer's yeast and fulvic acid is widely available as well. These supplements are not subject to the vagaries of weather-influence growing seasons as is the case with blue green algae and brown seaweed. When combined, beta glucan and fulvic acid can provide a less costly dietary supplement than blue green algae and brown seaweed and its derivatives such as fucoidan.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Cappellos, Inc.
    Inventor: John V. Cappello
  • Publication number: 20140276493
    Abstract: Provided herein are biologically active solution compositions comprising one or more sacrificial proteolytic enzyme substrates, one or more preservatives, and one or more antimicrobial agents and methods of using the solution compositions to treat tissue sites, in particular chronic wounds. The compositions may be used in conjunction with negative pressure wound therapy to treat tissue sites.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Braden King-Fung Leung, Ona Whelove, Chester R. Edlund, John R. Harper
  • Publication number: 20140271930
    Abstract: A noninvasive method for diagnosing skin health in a subject comprising collecting a skin sample from the subject; detecting a level of one or more small molecule biomarkers in the epithelial cell sample/skin cell sample; diagnosing the subject as having a skin condition based on the level of a detected small molecule biomarker, wherein the detected small molecule is at least one compound chosen from: a compound generated by metabolism of amino acids, a compound generated by dipeptides metabolism, a compound generated by nucleic acids, a compound generated by metabolism of lipids, a compound generated by metabolism of carbohydrates, and mixtures thereof and further small molecule biomarkers as listed in Table 1. Further, a noninvasive method for evaluating the efficacy of products for skin health.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Kathleen Marie KERR, Kenneth Robert WEHMEYER, Feng WANG, Angela Marie FIENO, Kevin John MILLS
  • Publication number: 20140255509
    Abstract: Compositions and formulations comprising a non-neutralised tocol phosphate and a vitamin A compound, which are suitable for the treatment of inflammation and/or infection in breast or udder tissue, more particularly in a mammary gland, reducing the somatic cell count in a lactating subject and supplementing vitamin E levels in a subject.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 11, 2014
    Applicant: PHOSPHAGENICS LIMITED
    Inventors: Roksan Libinaki, Robert Lee Neely
  • Publication number: 20140255511
    Abstract: The present invention generally relates to the field of medical nutrition. For example, the present invention provides a composition that can be used to treat, prevent and/or reverse muscle atrophy related to immobilization and its consequences. One embodiment of the present invention concerns a composition comprising a leucine and antioxidants that can be used in accelerating muscle recovery after muscle atrophy.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 11, 2014
    Inventors: Dominique Dardevet, Isabelle Savary-Auzeloux, Didier Remond, Lydie Combaret, Gary Williamson, Magali Faure, Denis Breuille
  • Publication number: 20140212507
    Abstract: Disclosed is a method for determining a supplement regime for a subject diagnosed with age-related macular degeneration (AMD). The method involves determining the subject's risk of developing advanced AMD based on their genetic profile for the complement factor H gene and the ARMS2 gene and administering a supplement containing antioxidants and/or zinc based on their risk of developing advanced AMD.
    Type: Application
    Filed: July 31, 2013
    Publication date: July 31, 2014
    Applicant: ArcticDx Inc.
    Inventors: Brent Zanke, Carl Awh
  • Publication number: 20140212515
    Abstract: Compositions and methods of treating carcinoma in an individual afflicted with such a condition, comprising the administration to the individual a therapeutically effective amount of a composition consisting essentially of a nutraceutically acceptable carrier and sodium selenite, with or without menadione. The administration may be sublingual and may be performed in conjunction with injection, into the solid tumor where the carcinoma is a solid tumor, or by intra-arterial catheterization or an organ specific artery where the carcinoma is organ specific, or both.
    Type: Application
    Filed: January 31, 2013
    Publication date: July 31, 2014
    Inventor: Mark Ira Simon
  • Publication number: 20140205642
    Abstract: A method of preparing antimicrobial-containing polymeric products is provided, the method involving electrospinning a dispersion comprising a dispersible polymer, a fiberizing polymer, and one or more antimicrobial agents. The electrospun material is heated to remove solvent and the fiberizing polymer, giving a nonwoven polymeric material having antimicrobial agent incorporated therein. The material can be in the form of, for example, a non-woven sheet, tube, or covering.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 24, 2014
    Applicant: Zeus Industrial Products, Inc.
    Inventors: Robert L. Ballard, Bruce L. Anneaux, Joshua L. Manasco
  • Publication number: 20140193485
    Abstract: The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with ACE inhibitors in order to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with lisinopril in particular.
    Type: Application
    Filed: February 5, 2014
    Publication date: July 10, 2014
    Applicant: YOUR ENERGY SYSTEMS, LLC
    Inventor: Frederick Timothy Guilford
  • Patent number: 8758835
    Abstract: It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: June 24, 2014
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Franco Gaetani, Ashraf Virmani
  • Publication number: 20140147515
    Abstract: A composition for preventing or reducing harmful effects of protozoal infection is provided, comprising in one embodiment a yeast cell wall and a preparation derived from oregano. The composition may further include a mineral nutrient selected from selenium and/or zinc. The composition may also include a preparation derived from Yucca. Efficacy of the composition is shown against a variety of protozoal organisms.
    Type: Application
    Filed: July 21, 2004
    Publication date: May 29, 2014
    Applicant: Alltech, Inc.
    Inventors: Cepta Duffy, Aidan Joseph Connolly
  • Publication number: 20140141071
    Abstract: The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicant: YOUR ENERGY SYSTEMS, LLC
    Inventor: Frederick Timothy Guilford
  • Publication number: 20140141104
    Abstract: Use of selenate or a pharmaceutically acceptable salt thereof in methods and compositions for enhancing the activity of the protein phosphatase PP2A is provided. Methods of reducing phosphorylation of tau protein, inhibiting activity of GSK3 and treating or preventing neurodegenerative diseases are also described.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 22, 2014
    Applicant: Velacor Therapeutics Pty Ltd
    Inventors: Christopher Hovens, Niall Corcoran
  • Patent number: 8728539
    Abstract: Disclosed is a method of enhancing absorption (pinocytosis efficiecy) of immunoglobulins administered to postnatal domestic mammals (e.g., bovine) by using selenium. As an example of a selenium compound added, sodium selenite is particularly effective.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 20, 2014
    Assignee: Incorporated Administrative Agency, National Agriculture and Bio-Oriented Research Organization
    Inventors: Hachiro Kamada, Itoko Nonaka
  • Publication number: 20140127179
    Abstract: A formulation of supplement is able to boost the natural cells, both increasing the population of the natural cells and enhancing the natural cell's activity. The formulation can be administered via different forms, such as tablet, injection, skin absorption and etc. This formulation comprises 16 different components, including Alpha Lipoic Acid, Arabinoxylin, Curcumin, Garlic, Genistein, Ginseng, Lentinan, Mistletoe, N-Acetylcysteine, Resveratrol, Selenium, Vitamin B Complex, Vitamin C, Vitamin D3, Vitamin E and Zinc. By virtue of enhancing the natural killer cells (NKC) in the body, the formation is helpful for the prevention and treatment of a number of different human or animal diseases, such as cancers and viral infections. In addition, certain synergistic effects have been observed between different components in the formulation, which further enhances the beneficial effect of the formulation.
    Type: Application
    Filed: November 4, 2013
    Publication date: May 8, 2014
    Applicant: SCIENTIFIC FORMULATIONS, LLC
    Inventor: Jerry Thomas THORNTHWAITE
  • Patent number: 8697143
    Abstract: A composition for durable non-permanent shaping or durable retention of a non-permanent shape of least one keratinous fiber comprising: (a) at least one film forming agent; and (b) at least one saccharide type compound chosen from C3 to C5 monosaccharides, optionally substituted with at least one C1 to C22 carbon chain, and compounds comprising at least one C5 to C7 saccharide unit substituted with at least one amino group.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: April 15, 2014
    Assignee: L'Oreal
    Inventors: Nghi Nguyen, David W. Cannell